Mazdutide
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Innovent · Phase 2 · Completed · Enrollment 179
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 3/6 Milligrams (mg) Mazdutide | n/r | n/r | n/r | n/r |
| 10 mg Mazdutide | n/r | n/r | n/r | n/r |
| 16 mg Mazdutide | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
| 3/6 mg Mazdutide | n/r | n/r | n/r | n/r |
Not shown
- 3/6 Milligrams (mg) Mazdutide: endpoint not reported
- 10 mg Mazdutide: endpoint not reported
- 16 mg Mazdutide: endpoint not reported
- Placebo: endpoint not reported
- 3/6 mg Mazdutide: endpoint not reported